Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07469800 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 27, 2026 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Recruitment opened Start date changed from estimate of Apr 1, 2026 to Apr 23, 2026 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Apr 1, 2026 to Apr 23, 2026
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A multicenter, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of IBI362 in participants with mild to moderate hypertension complicated by overweight/obesity who have not received antihypertensive drug treatment
Trial Details
NCT Number NCT07469800
Lead Sponsor Innovent Biologics (Suzhou) Co. Ltd.
Conditions Overweight, Obesity, Hypertensive
Enrollment 336 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov